Lasa Supergenerics Limited confirmed that all seven resolutions passed at its 11th Annual General Meeting received approval from 99.99% of valid votes cast. The consolidated scrutinizer report, submitted to stock exchanges on October 1, 2026, verified the results of the meeting held on September 30, 2026.

The meeting, conducted via Video Conferencing, addressed governance and operational financing matters. Dr. Omkar Herlekar, Chairman and Managing Director, presided over the session which concluded at 9:58 am. A total of 41 voters participated in the voting process, casting votes on behalf of 2,69,13,986 shares.

Voting Results Breakdown

The scrutinizer, M/s Shravan A. Gupta & Associates, reported negligible dissent across all items. The table below summarizes the voting outcomes for key resolutions:

Key Governance Approvals

Shareholders approved the appointment of Janardan Savla as a whole-time director and executive director for a five-year term commencing August 26, 2026. Additionally, special resolutions were passed to approve managerial remuneration in cases of inadequate profits and to enhance secured and unsecured borrowing powers.

The board also secured approval for donations to trusts and institutions, including the Dr Omkar Herlekar Foundation. Mr. Shivam Sharma of M/s Shivam Sharma & Associates was appointed as secretarial auditor for a term of five consecutive years.

Procedural Compliance

Remote e-voting facilities were provided by Bigshare Services Private Limited. The voting window opened on September 27, 2026, and closed on September 29, 2026. Members holding equity shares as of the cut-off date of September 23, 2026, were entitled to vote. The company stated that detailed voting results are available on its website, www.lasalabs.com .

What the Numbers Show

The uniformity of the voting results, with every resolution passing at exactly 99.99% in favour and 0.01% against, indicates a highly aligned shareholder base. Only 15 shares voted against the first four resolutions, while slightly more (80 shares) opposed the donation resolution and 90 shares opposed the managerial remuneration clause. This marginal increase in dissent on remuneration and related-party donation items suggests minor shareholder sensitivity to these specific governance provisions, though not enough to impact the outcome.

Lasa Supergenerics Limited (NSE: LASA) reported a net loss of ₹3,409.03 lakh for FY26, a significant increase from the net loss of ₹1,475.73 lakh recorded in FY25. The pharmaceutical manufacturer’s revenue from operations plummeted to ₹2,514.07 lakh, down sharply from ₹14,244.81 lakh in the prior year.

The company's operational status remains critical following a fire incident at its manufacturing facility on May 18, 2025. Consequently, production activities have been completely suspended. The Board of Directors highlighted that resuming operations is contingent upon obtaining statutory clearances and securing adequate financial resources.

Financial Performance

The decline in revenue was accompanied by substantial exceptional items, primarily due to uninsured losses from the fire. The company recognized an ad-hoc provisional impairment loss of ₹700 lakh on property, plant, and equipment, alongside inventory damage and other related expenses.

Exceptional items for the year totaled ₹2,103.75 lakh, compared to ₹1,566.91 lakh in FY25. These figures include the write-off of capital work-in-progress amounting to ₹46.27 lakh, which was deemed non-viable.

What the Numbers Show

The financial data reveals a severe liquidity contraction alongside operational paralysis. Liquid assets stood at just ₹69.66 lakh as of March 31, 2026, a decrease from ₹79.03 lakh in the previous year. With operations halted and no new revenue generation from manufacturing, the company is relying on asset disposals and borrowing to meet recurring expenditures and settle outstanding liabilities. Current borrowings rose significantly to ₹974.73 lakh from ₹212.75 lakh in FY25, indicating increased reliance on debt to manage cash flow constraints during this period of suspension.

Corporate Governance and Compliance

Lasa Supergenerics disclosed several regulatory non-compliances during FY26. The company failed to submit shareholding patterns, shareholder complaint statements, and quarterly corporate governance reports within the prescribed timelines for the quarter ended March 31, 2026. These delays resulted in penalties levied by both the National Stock Exchange and the Bombay Stock Exchange.

Additionally, the office of the Company Secretary remained vacant from August 29, 2025, to December 15, 2025, leading to non-compliance with SEBI Listing Regulations. Mrs. Mitti Jain was appointed as Company Secretary and Compliance Officer on December 16, 2025.

Board Changes

The company underwent significant changes in its key managerial personnel during the year. Mr. Prathamesh Chalke resigned as Whole-time Director on December 31, 2025. Mr. Ganesh Suresh Potdar served as an Additional Director from January 2, 2026, before resigning on August 25, 2026. Mr. Janardan Savala was appointed as an Additional Director on August 26, 2026, and is seeking approval for his appointment as Executive Director at the upcoming Annual General Meeting.

Auditor's Report

Statutory auditors Gupta Rustagi & Co. issued a qualified opinion on the financial statements. The qualification stems from the inability to determine the full financial impact of the fire incident due to incomplete assessment of damaged assets. Furthermore, the auditors noted that the company had not carried out impairment assessments for intangible assets, including patents and goodwill, despite indicators of impairment existing.